Concept scores are derived automatically based on a person's publications. Keywords in the their attributed publications are matched to keywords from the National Library of Medicine's controlled vocabulary thesaurus, MeSH (Medical Subject Headings). The strength of a person's concept scores is based not only on the number of corresponding publications, but also how relevant the concepts are to the overall topics of the publications, how long ago the publications were written, whether the person was the first or senior author, and how many other people have written about the topic.Concepts cannot be directly edited. You can help ensure your concepts are accurate by making sure your attributed publications are correct and up-to-date. We recommend checking over your attributed publications list every three to four months.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Chronic Pain | 4 | 2024 | 151 | 1.550 |
Why?
|
| Medication Adherence | 4 | 2016 | 133 | 1.460 |
Why?
|
| Analgesics, Opioid | 7 | 2024 | 500 | 1.160 |
Why?
|
| Palliative Care | 4 | 2020 | 188 | 1.160 |
Why?
|
| Pharmacists | 2 | 2019 | 152 | 1.110 |
Why?
|
| Computers, Handheld | 2 | 2013 | 27 | 0.910 |
Why?
|
| Tramadol | 4 | 2024 | 28 | 0.880 |
Why?
|
| Health Personnel | 3 | 2016 | 247 | 0.850 |
Why?
|
| Opioid-Related Disorders | 3 | 2023 | 367 | 0.820 |
Why?
|
| Drug Overdose | 2 | 2022 | 154 | 0.780 |
Why?
|
| Guidelines as Topic | 1 | 2019 | 124 | 0.670 |
Why?
|
| Health Literacy | 1 | 2016 | 137 | 0.470 |
Why?
|
| Sulfonamides | 1 | 2014 | 146 | 0.440 |
Why?
|
| Pyrimidines | 1 | 2014 | 196 | 0.430 |
Why?
|
| Clinical Competence | 1 | 2016 | 444 | 0.430 |
Why?
|
| Health Knowledge, Attitudes, Practice | 1 | 2016 | 538 | 0.400 |
Why?
|
| Neuralgia | 2 | 2023 | 58 | 0.390 |
Why?
|
| Melanoma | 1 | 2014 | 313 | 0.370 |
Why?
|
| Students, Pharmacy | 2 | 2023 | 147 | 0.330 |
Why?
|
| Education, Pharmacy | 2 | 2023 | 165 | 0.320 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 1 | 2014 | 1060 | 0.310 |
Why?
|
| Humans | 20 | 2024 | 54304 | 0.300 |
Why?
|
| Antineoplastic Agents | 1 | 2016 | 1300 | 0.290 |
Why?
|
| United States | 5 | 2023 | 5204 | 0.290 |
Why?
|
| Pharmaceutical Services | 2 | 2018 | 57 | 0.290 |
Why?
|
| Pharmacy | 2 | 2023 | 64 | 0.240 |
Why?
|
| Breast Neoplasms | 2 | 2023 | 1248 | 0.230 |
Why?
|
| Retrospective Studies | 10 | 2024 | 6462 | 0.220 |
Why?
|
| Gastrointestinal Hemorrhage | 1 | 2021 | 80 | 0.190 |
Why?
|
| Cyclohexanecarboxylic Acids | 1 | 2020 | 21 | 0.190 |
Why?
|
| Cross-Sectional Studies | 2 | 2016 | 1693 | 0.190 |
Why?
|
| Acetaminophen | 1 | 2022 | 350 | 0.170 |
Why?
|
| Hydrocodone | 3 | 2024 | 17 | 0.170 |
Why?
|
| Oxycodone | 3 | 2024 | 24 | 0.170 |
Why?
|
| Epidemics | 1 | 2018 | 19 | 0.170 |
Why?
|
| Cohort Studies | 2 | 2022 | 1547 | 0.170 |
Why?
|
| History, 21st Century | 1 | 2018 | 62 | 0.170 |
Why?
|
| Ambulatory Care Facilities | 1 | 2019 | 138 | 0.170 |
Why?
|
| College Admission Test | 1 | 2018 | 16 | 0.170 |
Why?
|
| History, 20th Century | 1 | 2018 | 114 | 0.160 |
Why?
|
| Adult | 6 | 2024 | 14189 | 0.160 |
Why?
|
| School Admission Criteria | 1 | 2018 | 37 | 0.160 |
Why?
|
| Critical Illness | 1 | 2021 | 343 | 0.160 |
Why?
|
| Schools, Pharmacy | 1 | 2018 | 68 | 0.160 |
Why?
|
| Pain Management | 1 | 2018 | 155 | 0.150 |
Why?
|
| Patient Care Team | 1 | 2019 | 273 | 0.150 |
Why?
|
| Cannabis | 1 | 2019 | 149 | 0.150 |
Why?
|
| Educational Measurement | 1 | 2018 | 232 | 0.140 |
Why?
|
| Herb-Drug Interactions | 1 | 2016 | 30 | 0.140 |
Why?
|
| Reminder Systems | 1 | 2016 | 30 | 0.140 |
Why?
|
| Medication Therapy Management | 1 | 2016 | 24 | 0.140 |
Why?
|
| Drug Interactions | 1 | 2016 | 206 | 0.130 |
Why?
|
| Emergency Service, Hospital | 1 | 2019 | 540 | 0.130 |
Why?
|
| Self Report | 1 | 2016 | 200 | 0.130 |
Why?
|
| Administration, Oral | 1 | 2016 | 461 | 0.130 |
Why?
|
| Community Pharmacy Services | 1 | 2016 | 70 | 0.130 |
Why?
|
| Carboplatin | 1 | 2014 | 63 | 0.120 |
Why?
|
| Indazoles | 1 | 2014 | 55 | 0.120 |
Why?
|
| Middle Aged | 3 | 2019 | 13076 | 0.110 |
Why?
|
| Quality of Life | 1 | 2019 | 922 | 0.110 |
Why?
|
| Female | 5 | 2023 | 28457 | 0.100 |
Why?
|
| Medicare | 2 | 2023 | 245 | 0.100 |
Why?
|
| Aged | 3 | 2023 | 10054 | 0.090 |
Why?
|
| Neoplasms | 1 | 2019 | 1321 | 0.090 |
Why?
|
| Male | 3 | 2019 | 27335 | 0.080 |
Why?
|
| Curriculum | 2 | 2023 | 432 | 0.080 |
Why?
|
| Ibuprofen | 1 | 2022 | 28 | 0.060 |
Why?
|
| Thyroid Gland | 1 | 2022 | 96 | 0.050 |
Why?
|
| Propensity Score | 1 | 2022 | 137 | 0.050 |
Why?
|
| Pain, Postoperative | 1 | 2022 | 160 | 0.050 |
Why?
|
| Guideline Adherence | 1 | 2023 | 148 | 0.050 |
Why?
|
| Health Care Costs | 1 | 2022 | 176 | 0.050 |
Why?
|
| Infusions, Intravenous | 1 | 2021 | 231 | 0.050 |
Why?
|
| Amines | 1 | 2020 | 46 | 0.050 |
Why?
|
| Pilot Projects | 1 | 2022 | 805 | 0.050 |
Why?
|
| Intensive Care Units | 1 | 2021 | 232 | 0.040 |
Why?
|
| Case-Control Studies | 1 | 2023 | 1229 | 0.040 |
Why?
|
| Analgesics | 1 | 2020 | 107 | 0.040 |
Why?
|
| Outpatients | 1 | 2020 | 122 | 0.040 |
Why?
|
| Pain | 1 | 2022 | 404 | 0.040 |
Why?
|
| Follow-Up Studies | 1 | 2024 | 2389 | 0.040 |
Why?
|
| Universities | 1 | 2018 | 163 | 0.040 |
Why?
|
| Prospective Studies | 1 | 2022 | 2604 | 0.030 |
Why?
|
| Arkansas | 1 | 2022 | 2097 | 0.030 |
Why?
|
| Young Adult | 1 | 2018 | 4313 | 0.020 |
Why?
|